(HealthDay)—Among men with very-low-risk prostate cancer (PCa) who meet criteria for active surveillance but undergo radical prostatectomy, African-American race is associated with poorer outcomes, with ...
not rated yet |
0
Researchers have found that antibodies against the human papillomavirus (HPV) may help identify individuals who are at greatly increased risk of HPV-related cancer of the oropharynx, which is a portion of ...
5 / 5 (1) |
0
|
(HealthDay)—For patients with cancer with Clostridium difficile-associated diarrhea (CDAD), fidaxomicin treatment is associated with improved outcomes compared with vancomycin treatment, according to res ...
not rated yet |
0
(HealthDay)—Medical oncologists (MOs) and primary care physicians (PCPs) report different barriers/concerns in cancer follow-up care to be problematic, according to research published online May 20 in the ...
not rated yet |
0
(HealthDay)—A case of acquired resistance to crizotinib has been described in a patient with metastatic lung adenocarcinoma harboring a CD74-ROS1 rearrangement, according to a brief report published online ...
not rated yet |
0
Even if Australians with newly diagnosed bowel cancer were routinely tested for a genetic predisposition to further cancers, one in three people would still not take the necessary steps to use that information to prevent ...
not rated yet |
0
The combination of the immunotherapy drug ipilimumab and the investigational antibody drug nivolumab led to long-lasting tumor shrinkage in more than half of patients with metastatic melanoma, according to results from a ...
not rated yet |
0
(HealthDay) -- For patients with metastatic melanoma with activating mutations in serine-threonine protein kinase B-RAF (BRAF), treatment with the oral selective MEK inhibitor trametinib is associated with ...
not rated yet |
0
(HealthDay) -- It remains unclear whether the benefits of prostate-specific antigen (PSA) testing outweigh the harms, but evidence suggests that men with a longer life expectancy may benefit from testing, ...
not rated yet |
3
|
In the largest study of its kind to date, Stanford University School of Medicine researchers have shown that women related to a patient with a breast cancer caused by a hereditary mutation -- but who don't have the mutation ...
not rated yet |
0
|
(Medical Xpress)—A drug which for decades has been widely used to treat pain related to cancer has no net clinical benefit, researchers in the Palliative Care Clinical Studies Collaborative (PaCCSC) based ...
3.7 / 5 (3) |
0
(HealthDay)—In patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC), low HCV viral load predicts better long-term surgical outcomes, regardless of the serologic eradication of HCV, ...
not rated yet |
0
(Medical Xpress)—A Phase 2 clinical trial testing a new protocol for treating a relatively rare form of brain cancer, primary CNS lymphoma, may change the standard of care for this disease, according to ...
not rated yet |
0
|
Treatment with three relatively new "targeted" cancer drugs has been linked to a slightly elevated chance of fatal side effects, according to a new analysis led by scientists at Dana-Farber Cancer Institute. They added that ...
5 / 5 (1) |
0
|
(HealthDay)—Smoking is tied to significantly shorter disease-free survival (DFS) and time to recurrence (TTR) in patients undergoing treatment for stage III colon cancer, according to a study published ...
5 / 5 (1) |
2
The Journal of Clinical Oncology (JCO) is a medical journal published by the American Society of Clinical Oncology (ASCO). The Journal was founded in 1983 and publishes original research and review articles on topics relating to cancer. It is published 3 times a month. The Journal's impact factor in 2007 was 15.484, making it one of the highest-impact journals in the field of oncology.
This text uses material from Wikipedia licensed under CC BY-SA
